Myelodysplastic Syndrome Associated with Myelofibrosis, A Report of 3 Cases.

Kamei, Shinji; Shinohara, Kenji; Oeda, Eiichi

doi:10.2169/internalmedicine.32.668

Cited by 5 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, there have been a few similar reports of "transitional" [13] MDS→PMF [10,[13][14][15][16][17], although ours may be the first documented in the JAK2 molecular era. A model is presented in Fig.…”

Section: Bm Fibrosis Has Long Been Associated With Mds [2-5]mentioning

confidence: 66%

“…However, in our case, the appearance of fibrosis coincided with the loss of MDS-associated RS and del(20q). Furthermore, there have been descriptions of MDS patients transitioning to acute panmyelosis with myelofibrosis (APMF) [8][9][10]. However, APMF is characterized by an abrupt onset with fever and bone pain, with no to minimal splenomegaly, more numerous megakaryocytes and leukemic level (≥20%) blasts [1].…”

Section: Bm Fibrosis Has Long Been Associated With Mds [2-5]mentioning

confidence: 99%

See 1 more Smart Citation

Emergence of JAK2-mutant primary myelofibrosis in myelodysplastic syndrome: rare case report, literature review, and implications for clonal progression

et al. 2011

View full text Add to dashboard Cite

Section: Bm Fibrosis Has Long Been Associated With Mds [2-5]mentioning

confidence: 66%

Section: Bm Fibrosis Has Long Been Associated With Mds [2-5]mentioning

confidence: 99%

Emergence of JAK2-mutant primary myelofibrosis in myelodysplastic syndrome: rare case report, literature review, and implications for clonal progression

et al. 2011

View full text Add to dashboard Cite

“…2). There are some reports that anabolic‐androgenic steroids, such as methenolone, are effective in the management of MDS 8 . In contrast, there is only one old report from 1987 regarding the response to testosterone for patients with MDS 9 .…”

Section: Discussionmentioning

confidence: 99%

Myelodysplastic syndrome treated effectively with testosterone enanthate

et al. 2011

View full text Add to dashboard Cite

Abstract:We report a case of myelodysplastic syndrome (MDS) treated effectively with testosterone enanthate. A 70-year-old man was diagnosed with low-risk MDS in 1998, and he was first given methenolone acetate orally because of gradual progression of anemia and thrombocytopenia. However, this treatment was not effective, so we changed the treatment to testosterone enanthate because of his symptoms with late-onset hypogonadism. Three months after testosterone replacement therapy (TRT), anemia and thrombocytopenia had improved , and mean platelet count and hemoglobin had significant increases from 2.36 Ϯ 0.45 ¥ 10 4 to 3.83 Ϯ 0.78 ¥ 10 4 /mL, and from 11.7 Ϯ 0.81 to 15.2 Ϯ 1.00 g/ dL, respectively, which contributed to a decrease in platelet transfusion requirement. Since then, the patient has been on a good clinical course. The present case suggests that testosterone enanthate administration could be an alternative treatment for men with MDS, even in the case where treatment with anabolic-androgenic steroids is not successful, and suggests another interesting effect of TRT on platelets.

show abstract

“…Such changes might indicate a severe disturbance of lineage‐specific maturation and therefore may herald acceleration of the disease process in some patients. Furthermore, because of the similarity of relevant lesions, pronounced dysmegakaryopoiesis can create significant difficulties in discriminating myelodysplastic syndromes (MDS) with accompanying BM fibrosis 31–33 from IMF following cytoreductive treatment. Therefore, caution has to be exercised when diagnosing so‐called overlapping myeloproliferative and myelodysplastic syndromes, particularly in the absence of a full clinical history.…”

Section: Discussionmentioning

confidence: 99%